<p>W = week, W0 and W24 are vaccination visits.</p>a<p>(V/P) Number of Vaccine recipients/number of Placebo recipients per group.</p>b<p>Screen window up to 65 days prior to enrollment for anti-Ad35 antibodies.</p>c<p>Serum neutralizing antibodies against Ad35.</p>d<p>Vaccine-induced HIV-1 specific IFN-γ ELISPOT responses.</p>e<p>Vaccine-induced HIV-1 specific humoral immune responses (Env and p24 Gag ELISA).</p>f<p>Polychromatic Flow Cytometry.</p
A Phase I HIV-1 vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was cond...
<p>Antigens recognized by HIV-specific antibodies as determined by HIV Western blot assay by group a...
<p>HIV-RNA with a limit of detection of 50 copies/ml is shown as black dots, HIV-RNA ultrasensitive ...
<p>Serum samples collected at regular intervals during the vaccination schedule from Ad5-seronegativ...
Frequency of vaccine-specific CD4+ T cells measured at different time points. The mean value of the ...
Frequency of vaccine-specific CD8+ T cells at different time points. The mean value of the total res...
<p>Volunteers were given ChAdV63.HIVconsv alone or as a part of a heterologous prime-boost regimen a...
Background: Vaccine-induced antibodies to envelope proteins frequently cause HIV seroconversion in u...
<p>Volunteers were given ChAdV63.HIVconsv alone or as a part of a heterologous prime-boost regimen a...
Candidate HIV vaccines are designed to induce antibodies to various components of the HIV virus. An ...
<p>Panel A, CD4+ IFN-γ response 8 weeks after receiving the first vaccine dose. Number of cells quan...
<p>Panel A) HIV-Env subtype A (UG37) and panel B) HIV-Env subtype B (6101) specific IgG antibody tit...
A Phase I HIV-1 vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was cond...
Elevated risk of HIV-1 infection among recipients of an adenovirus serotype 5 (Ad5)-vectored HIV-1 v...
<p>IgG and IgA responses and percentage of responders to the gD protein measured at week 26 by bindi...
A Phase I HIV-1 vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was cond...
<p>Antigens recognized by HIV-specific antibodies as determined by HIV Western blot assay by group a...
<p>HIV-RNA with a limit of detection of 50 copies/ml is shown as black dots, HIV-RNA ultrasensitive ...
<p>Serum samples collected at regular intervals during the vaccination schedule from Ad5-seronegativ...
Frequency of vaccine-specific CD4+ T cells measured at different time points. The mean value of the ...
Frequency of vaccine-specific CD8+ T cells at different time points. The mean value of the total res...
<p>Volunteers were given ChAdV63.HIVconsv alone or as a part of a heterologous prime-boost regimen a...
Background: Vaccine-induced antibodies to envelope proteins frequently cause HIV seroconversion in u...
<p>Volunteers were given ChAdV63.HIVconsv alone or as a part of a heterologous prime-boost regimen a...
Candidate HIV vaccines are designed to induce antibodies to various components of the HIV virus. An ...
<p>Panel A, CD4+ IFN-γ response 8 weeks after receiving the first vaccine dose. Number of cells quan...
<p>Panel A) HIV-Env subtype A (UG37) and panel B) HIV-Env subtype B (6101) specific IgG antibody tit...
A Phase I HIV-1 vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was cond...
Elevated risk of HIV-1 infection among recipients of an adenovirus serotype 5 (Ad5)-vectored HIV-1 v...
<p>IgG and IgA responses and percentage of responders to the gD protein measured at week 26 by bindi...
A Phase I HIV-1 vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was cond...
<p>Antigens recognized by HIV-specific antibodies as determined by HIV Western blot assay by group a...
<p>HIV-RNA with a limit of detection of 50 copies/ml is shown as black dots, HIV-RNA ultrasensitive ...